Intellia Therapeutics, Inc. (NTLA)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
15.30 USD
+0.09
(0.592%)
⇧
(April 21, 2026, 11:04 a.m.
EDT)
Short-term: ☆☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:43 a.m. EDT
NTLA appears to be a high-beta biotech swing trade rather than a safe investment. While fundamentals are weak (negative earnings, high cash burn), the technicals show strong recovery from a $11.65 low to $14.95, aligning with a 'buy the rumor, sell the news' strategy around upcoming clinical updates. The lack of 0% IV for distant puts and the heavy call inventory at July strikes suggests traders are pricing in a recovery, but the negative 45-day forecast model (-7.92%) warns of volatility and potential traps ahead of earnings. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.092880 |
| AutoETS | 0.117419 |
| AutoARIMA | 0.117425 |
| MSTL | 0.137702 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 79% |
| H-stat | 0.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.649 |
| Excess Kurtosis | 0.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.901 |
| Revenue per Share | 0.624 |
| Market Cap | 1,807,443,200 |
| Forward P/E | -5.24 |
| Beta | 1.99 |
| Website | https://www.intelliatx.com |
As of April 19, 2026, 12:43 a.m. EDT: Speculators are displaying a distinct bullish skew in open interest (OI), establishing a major wall at $25-strikes for April and $18-19 strikes for July expirations. Unusual warrants exist for deep out-of-the-money calls ($1.00, .$4.00, .$42.00) indicating leverage play for significant upside moves. Conversely, put activity is heavy in the weekly contract ($10 strikes), suggesting a 'safety floor' or hedging strategy rather than a bearish reversal thesis, as the deep OTM put IVs are inflated but volume is lower than the OTM call flow.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8303249 |
| Address1 | 40 Erie Street |
| Address2 | Suite 130 |
| All Time High | 202.73 |
| All Time Low | 5.9 |
| Ask | 19.72 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 2,694,950 |
| Average Daily Volume3 Month | 4,105,214 |
| Average Volume | 4,105,214 |
| Average Volume10Days | 2,694,950 |
| Beta | 1.992 |
| Bid | 11.3 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.772 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.3 |
| Current Ratio | 5.08 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 15.9103 |
| Day Low | 15.22 |
| Debt To Equity | 13.901 |
| Display Name | Intellia Therapeutics |
| Earnings Call Timestamp End | 1,772,110,800 |
| Earnings Call Timestamp Start | 1,772,110,800 |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -431,223,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.34 |
| Enterprise To Revenue | 21.283 |
| Enterprise Value | 1,440,256,256 |
| Eps Current Year | -3.55484 |
| Eps Forward | -2.92102 |
| Eps Trailing Twelve Months | -3.81 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.2853 |
| Fifty Day Average Change | 2.0147 |
| Fifty Day Average Change Percent | 0.1516488 |
| Fifty Two Week Change Percent | 83.032486 |
| Fifty Two Week High | 28.25 |
| Fifty Two Week High Change | -12.95 |
| Fifty Two Week High Change Percent | -0.45840707 |
| Fifty Two Week Low | 6.83 |
| Fifty Two Week Low Change | 8.47 |
| Fifty Two Week Low Change Percent | 1.2401172 |
| Fifty Two Week Range | 6.83 - 28.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,462,541,400,000 |
| Float Shares | 111,938,623 |
| Forward Eps | -2.92102 |
| Forward P E | -5.2378964 |
| Free Cashflow | -233,285,744 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 377 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -256,780,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04614 |
| Held Percent Institutions | 0.85435 |
| Implied Shares Outstanding | 118,133,547 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Intellia Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,807,443,200 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_277799796 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -412,694,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,796,811,234 |
| Number Of Analyst Opinions | 21 |
| Open | 15.45 |
| Operating Cashflow | -394,736,000 |
| Operating Margins | -4.28857 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 857 285 6200 |
| Previous Close | 15.21 |
| Price Eps Current Year | -4.3039913 |
| Price Hint | 2 |
| Price To Book | 2.6507277 |
| Price To Sales Trailing12 Months | 26.709272 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.422 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.08 |
| Region | US |
| Regular Market Change | 0.09000015 |
| Regular Market Change Percent | 0.591717 |
| Regular Market Day High | 15.9103 |
| Regular Market Day Low | 15.22 |
| Regular Market Day Range | 15.22 - 15.9103 |
| Regular Market Open | 15.45 |
| Regular Market Previous Close | 15.21 |
| Regular Market Price | 15.3 |
| Regular Market Time | 1,776,783,898 |
| Regular Market Volume | 1,694,568 |
| Return On Assets | -0.27113 |
| Return On Equity | -0.5348 |
| Revenue Growth | 0.788 |
| Revenue Per Share | 0.624 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 118,133,546 |
| Shares Percent Shares Out | 0.32970002 |
| Shares Short | 38,945,982 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 44,306,166 |
| Short Name | Intellia Therapeutics, Inc. |
| Short Percent Of Float | 0.36900002 |
| Short Ratio | 8.95 |
| Source Interval | 15 |
| State | MA |
| Symbol | NTLA |
| Target High Price | 106.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 25.28571 |
| Target Median Price | 19.0 |
| Total Cash | 449,884,000 |
| Total Cash Per Share | 3.808 |
| Total Debt | 93,329,000 |
| Total Revenue | 67,671,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.81 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.04205 |
| Two Hundred Day Average Change | 2.2579498 |
| Two Hundred Day Average Change Percent | 0.17312844 |
| Type Disp | Equity |
| Volume | 1,694,568 |
| Website | https://www.intelliatx.com |
| Zip | 2,139 |